Allergan plc (AGN) Position Maintained by Thomas White International Ltd.

Joanna Estrada
July 28, 2017

(NYSE:AGN) opened at 254.16 on Friday. The fund purchased 2,200 shares of the company's stock, valued at approximately $526,000. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the company a "buy" rating in a research note on Thursday, June 8th. Caisse DE Depot ET Placement DU Quebec's holdings in Allergan PLC. were worth $1,064,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Veritas Asset Management LLP acquired a new stake in Allergan PLC. during the first quarter valued at $761,339,000. Schroder Investment Management Group increased its stake in shares of Allergan 133.3% in the first quarter. The Frontier Investment Mgmt Company holds 39,064 shares with $8.20 million value, down from 40,664 last quarter. Appaloosa LP boosted its stake in Allergan 249.8% in the fourth quarter. JNBA Financial Advisors now owns 487 shares of the company's stock valued at $116,000 after buying an additional 12 shares during the last quarter. JNBA Financial Advisors boosted its position in Allergan 2.5% in the first quarter. The fund owned 4,316 shares of the company's stock at the end of the first quarter. Within its US Specialized Therapeutics, US General Medicine and global operations, the Company sells its brand and aesthetic pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail-order retailers, government agencies and managed healthcare providers, such as health maintenance organizations and other institutions. The stock has advanced 38.83% to a low over the previous 12 months and showed declining move -1.96% to a high over the same period. The firm has a market cap of $82.57 billion, a price-to-earnings ratio of 7.66 and a beta of 1.16.

Investors have the option to employ technical indicators when conducting stock research. Volume in the last session has increased compared with AGN's average trading volume. The value of the investment in AGN decreased from $7,362,000 to $6,486,000 a change of 11.9% since the last quarter. The company reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.32 by $0.03. The company had revenue of $3.57 billion for the quarter, compared to analysts' expectations of $3.53 billion. During the same quarter a year ago, the business earned $3.04 earnings per share.

Let's take an assessment at how Allergan plc (AGN) has been performing. Finally, Webster Bank N.A. boosted its position in Allergan 31.0% in the first quarter. If you are accessing this article on another publication, it was copied illegally and reposted in violation of USA and worldwide copyright & trademark laws. The correct version of this news story can be read at "(NYSE:AGN)" was reported by Sports Perspectives and is the sole property of of Sports Perspectives. Credit Suisse Group reiterated an "outperform" rating and set a $286.00 price objective (up previously from $274.00) on shares of Allergan plc in a report on Thursday, July 20th. Deutsche Bank AG restated a "buy" rating and set a $273.00 price objective (up from $265.00) on shares of Allergan a research report on Monday, July 17th. 23,303 are held by Principal Group Inc. (The) downgraded shares of Allergan PLC. from a "buy" rating to a "neutral" rating and set a $262.00 target price on the a report on Wednesday, May 10th. (NYSE:AGN), 16 have Buy rating, 0 Sell and 6 Hold. The stock presently has a consensus rating of "Buy" and a consensus target price of $273.78. The firm owned 1,290 shares of the company's stock after buying an additional 320 shares during the period. Many traders will use moving averages for different periods of time in conjunction with other indicators to help gauge future stock price action. (NYSE:AGN) by 33.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Allergan Inc now has $86.03 billion valuation. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ's disease. Chartist Incorporated Ca holds 0% in Allergan plc Ordinary Shares (NYSE:AGN) or 1,562 shares.

Other reports by Click Lancashire

Discuss This Article